Abstract
Alirocumab, a Fully Human Monoclonal Antibody to PCSK9, Reduces High Plasma Lp(a) Concentration: Pooled Analysis of 352 Patients from Phase 2
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have